Almirall, Inserm Transfert enter agreement for vitiligo research

Almirall S.A. and Inserm Transfert have entered an agreement to advance research in vitiligo treatment, the two entities announced in a press release.
The licensing and research collaboration agreement will focus on developing medicines that modulate the Wnt pathway.
Inserm Transfert, a private subsidiary of the French National Institute of Health and Medical Research (Inserm), signed the collaboration agreement on behalf of Inserm, Centre Hospitalier Universitaire of Nice and University of Nice Côte d’Azur.
“Vitiligo can have a huge impact on patients' quality of life. We are

Almirall S.A. and Inserm Transfert have entered an agreement to advance research in vitiligo treatment, the two entities announced in a press release.
The licensing and research collaboration agreement will focus on developing medicines that modulate the Wnt pathway.
Inserm Transfert, a private subsidiary of the French National Institute of Health and Medical Research (Inserm), signed the collaboration agreement on behalf of Inserm, Centre Hospitalier Universitaire of Nice and University of Nice Côte d’Azur.
“Vitiligo can have a huge impact on patients’ quality of life. We are